Center for Human Genetics and Laboratory Diagnostics, Dr. Klein, Dr. Rost and Colleagues

You are here: Molecular Genetics » Hemophilia B

Hemophilia B [D67.0]

OMIM numbers: 306900, 300746 (F9)

Dipl.-Biol. Birgit Busse

Scientific Background

Hemophilia B is an X chromosomal recessive coagulation disorder, caused by a deficiency of the coagulation factor IX. It is the rarer form of classic hemophilia. The deficiency in factor IX results in a disorder in the intrinsic pathway of the coagulation cascade and leads to signs and symptoms of a hemorrhagic diathesis with prolonged aPTT time.

Hemophilia B cannot be distinguished from hemophilia A (factor VIII deficiency) regarding its phenotype. The two disorders are distinguished by biochemical measurement of the respective enzyme activity.

More than 1,000 mutations causing hemophilia B have been identified in the F9 gene. Depending on the mutation, the enzyme activity is impaired to varying degrees; therefore the disease is categorized into different degrees of severity.

  • Severe hemophilia B: factor IX activity <1%
  • Moderate hemophilia B: factor IX activity 1-5%
  • Mild hemophilia B: factor IX activity 5-15%
  • Sub-hemophilia B: factor IX activity 15-50%

Due to the X chromosomal inheritance pattern, mainly men are affected. The prevalence is estimated to be approx. 1 in 30,000. In rare cases, female heterozygous carriers with a skewed X inactivation may develop signs and symptoms as well. Treatment consists of intravenous administration of recombinant factor IX.